The BDP was established in 1993. We support the development of monoclonal antibodies,
recombinant proteins, therapeutic peptides and DNA vaccines, virus therapeutics
and vaccines, gene therapy products, and other biological agents. Since its inception
BDP has completed more than 100 projects. The program has released over 220 lots
of different products since 1997 and more than 60 agents have gone into human clinical
Our facilities are designed to be flexible, enabling us to work on multiple projects
for a variety of different indications. The BDP provides a unique NCI-funded resource
which differentiates it from other biopharmaceutical development programs: we concentrate
on products that are in early development, beginning with demonstrating product
feasibility on the bench through producing Phase I/II clinical supplies for first-in-human
The BDP makes available over 300 documents that are useful for any investigator,
company or group developing biopharmaceuticals. These documents can help scientific,
clinical manufacturing, quality control and quality assurance professionals. You
can request electronic copies of these BDP documents by clicking on the button below.
Occasionally academia and other government agencies use the BDP for training.
The BDP is developing clinical and non-clinical supplies of rhIL-15 and rhIL-7.
If you would like more information about obtaining supplies or manufacturing and
testing documentation please contact
Dr. Jason Yovandich.